Join
Live feed
·
PRReleasevia Quantisnow
Aprea Therapeutics Inc. logo

Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium

ByQuantisnow·Wall Street's wire, on your screen.
APRE· Aprea Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track APRE (Aprea Therapeutics Inc.) and more on Quantisnow.